DB:0ET

Stock Analysis Report

Executive Summary

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).


Snowflake Analysis

Adequate balance sheet with moderate growth potential.

Share Price & News

How has Esperion Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0ET's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.9%

0ET

8.1%

DE Biotechs

7.2%

DE Market


1 Year Return

-7.8%

0ET

-5.4%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 0ET underperformed the German Biotechs industry which returned -5.4% over the past year.

Return vs Market: 0ET exceeded the German Market which returned -17.5% over the past year.


Shareholder returns

0ETIndustryMarket
7 Day-6.9%8.1%7.2%
30 Day-39.1%-11.8%-22.3%
90 Day-38.2%-22.7%-26.1%
1 Year-7.8%-7.8%-5.2%-5.4%-14.9%-17.5%
3 Year-3.7%-3.7%17.6%16.3%-18.7%-25.7%
5 Year-65.1%-65.1%-5.1%-7.5%-17.8%-29.1%

Price Volatility Vs. Market

How volatile is Esperion Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Esperion Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 0ET (€32.47) is trading below our estimate of fair value (€134.06)

Significantly Below Fair Value: 0ET is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 0ET is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 0ET is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0ET's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0ET is overvalued based on its PB Ratio (48.6x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

14.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0ET is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0ET is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0ET is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0ET's revenue (28% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: 0ET's revenue (28% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 0ET's Return on Equity is forecast to be very high in 3 years time (421.4%).


Next Steps

Past Performance

How has Esperion Therapeutics performed over the past 5 years?

-21.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0ET is currently unprofitable.

Growing Profit Margin: 0ET is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0ET is unprofitable, and losses have increased over the past 5 years at a rate of -21.7% per year.

Accelerating Growth: Unable to compare 0ET's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0ET is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 0ET has a negative Return on Equity (-487.04%), as it is currently unprofitable.


Next Steps

Financial Health

How is Esperion Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 0ET's short term assets ($211.7M) exceed its short term liabilities ($66.1M).

Long Term Liabilities: 0ET's short term assets ($211.7M) exceed its long term liabilities ($128.4M).


Debt to Equity History and Analysis

Debt Level: 0ET's debt to equity ratio (664.4%) is considered high.

Reducing Debt: 0ET's debt to equity ratio has increased from 3.6% to 664.4% over the past 5 years.


Balance Sheet

Inventory Level: 0ET has a low level of unsold assets or inventory.

Debt Coverage by Assets: 0ET's debt is covered by short term assets (assets are 1.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0ET has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 0ET has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -21.4% each year.


Next Steps

Dividend

What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 0ET's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0ET's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0ET's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0ET's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0ET's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Tim Mayleben (58yo)

7.25s

Tenure

US$9,724,839

Compensation

Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biote ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD9.72M) is above average for companies of similar size in the German market ($USD1.36M).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Mayleben
President7.25yrsUS$9.72m0.41% $3.6m
Richard Bartram
CFO & Corporate Secretary2.17yrsUS$2.54m0.068% $594.3k
Mark Glickman
Chief Commercial Officer1.92yrsUS$9.12m0.094% $825.1k
Kenneth Fiorelli
Chief Technical Operations Officer0.50yrno datano data
Alexander Schwartz
Senior Director of Investor Relations1.83yrsno datano data
Regina Cavaliere
Chief Ethics & Compliance Officer0.67yrno datano data
Keith Lenden
Vice President of Corporate Development & Strategyno datano datano data
Renee Marotta
Head of Marketingno datano datano data
Ashley Hall
Chief Development Officer1.92yrsno data0.020% $175.0k
William Sasiela
Senior Vice President of Clinical Development1.92yrsno datano data

1.9yrs

Average Tenure

53yo

Average Age

Experienced Management: 0ET's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Timothy Mayleben
President7.25yrsUS$9.72m0.41% $3.6m
Daniel Janney
Independent Director7.33yrsUS$270.58k0.018% $158.1k
Nicole Vitullo
Lead Independent Director4.25yrsUS$311.66k0.030% $264.8k
Alan Fuhrman
Independent Non-Employee Directorno datano data0.0024% $20.8k
Antonio Gotto
Independent Director6.17yrsUS$290.84k0.018% $158.1k
Jay Shepard
Independent Director1.83yrsUS$477.34k0.018% $158.1k
Jeffrey Berkowitz
Director2.25yrsUS$1.41m0.018% $158.1k
Tracy Woody
Director0.83yrno data0.036% $316.2k
Mark McGovern
Independent Director6.08yrsUS$287.35k0.036% $317.3k

5.2yrs

Average Tenure

61yo

Average Age

Experienced Board: 0ET's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 0ET insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Esperion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Esperion Therapeutics, Inc.
  • Ticker: 0ET
  • Exchange: DB
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$970.914m
  • Listing Market Cap: US$875.667m
  • Shares outstanding: 27.51m
  • Website: https://www.esperion.com

Number of Employees


Location

  • Esperion Therapeutics, Inc.
  • 3891 Ranchero Drive
  • Suite 150
  • Ann Arbor
  • Michigan
  • 48108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ESPRNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2013
0ETDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2013
0IIMLSE (London Stock Exchange)YesCommon StockGBUSDJun 2013
0ETBRSE (Berne Stock Exchange)YesCommon StockCHCHFJun 2013

Biography

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/27 23:41
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.